News
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on the results of the phase III clinical trial True North. An open-label study followed this and previous clinical evaluations, focusing particularly on the efficacy of long-term use of ozanimod. What insights did the subsequent monitoring bring?
Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?
Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies…
MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication…
48 Tablets of Teriflunomide? Nothing Should Be Overdone! − Case Study
A case study published in the Journal of Clinical Pharmacy and Therapeutics describes an overdose…
Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor…
What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which…
Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective…
How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?
One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the…
Treatment of Schizophrenia in a Patient at Risk of Developing Metabolic Syndrome – Interactive Case Study
A 34-year-old man has been under psychiatric care for 3 years due to a psychotic disorder. Three years...
Currently on the Issue of Interchangeability of Preparations with Levothyroxine in Practice
Levothyroxine (LT4) in oral form is the standard therapy for patients with hypothyroidism. Given the...